| Schedule of financial data for the one reportable segment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
September 30, |
|
September 30, |
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
Research and development: |
|
|
|
|
|
|
|
|
|
|
|
|
Phase 2 study in B-cell malignancies, including WM and MM |
|
$ |
143,000 |
|
$ |
742,000 |
|
$ |
1,245,000 |
|
$ |
5,726,000 |
Phase 1 study in pediatric tumors |
|
|
225,000 |
|
|
769,000 |
|
|
1,175,000 |
|
|
2,428,000 |
Phase 1 study in triple negative breast cancer |
|
|
214,000 |
|
|
— |
|
|
265,000 |
|
|
— |
Manufacturing and related costs |
|
|
1,195,000 |
|
|
2,469,000 |
|
|
2,776,000 |
|
|
8,410,000 |
Pre-clinical projects cost |
|
|
72,000 |
|
|
49,000 |
|
|
724,000 |
|
|
101,000 |
General research and development costs |
|
|
674,000 |
|
|
1,465,000 |
|
|
2,155,000 |
|
|
3,262,000 |
General and administrative |
|
|
2,327,000 |
|
|
7,834,000 |
|
|
8,949,000 |
|
|
19,106,000 |
Other segment items |
|
|
(406,000) |
|
|
1,337,000 |
|
|
(793,000) |
|
|
3,193,000 |
Segment and consolidated net loss |
|
$ |
4,444,000 |
|
$ |
14,665,000 |
|
$ |
16,496,000 |
|
$ |
42,226,000 |
|